Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility

[1]  P. Albers,et al.  Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND) , 2021, World Journal of Urology.

[2]  D. Neal,et al.  A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections , 2021, World Journal of Urology.

[3]  R. Huddart,et al.  Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set , 2021, European urology open science.

[4]  C. Fankhauser,et al.  Nerve-sparing Robot-assisted Retroperitoneal Lymph Node Dissection: The Monoblock Technique , 2021, European urology open science.

[5]  S. Boorjian,et al.  SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. , 2021 .

[6]  K. Dieckmann,et al.  Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature , 2020, World Journal of Surgical Oncology.

[7]  T. Masterson,et al.  Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. , 2019, The Journal of urology.

[8]  R. Wahlqvist,et al.  Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. , 2020, European urology oncology.

[9]  Ramneek Gupta,et al.  Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Jewett,et al.  Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.031. , 2019, European urology.

[11]  L. Einhorn,et al.  Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. , 2019, European urology.

[12]  R. Bhanvadia,et al.  Lymph node count impacts survival following post‐chemotherapy retroperitoneal lymphadenectomy for non‐seminomatous testicular cancer: a population‐based analysis , 2019, BJU international.

[13]  P. Albers,et al.  The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment. , 2019, Journal of Clinical Oncology.

[14]  R. Huddart,et al.  Clinical outcomes of minimally invasive retroperitoneal lymph node dissection and single dose carboplatin for clinical stage IIa seminoma. , 2019, Journal of Clinical Oncology.

[15]  P. Warde,et al.  Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Scott C. Johnson,et al.  Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. , 2019, Urology.

[17]  F. Montorsi,et al.  The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. , 2018, European urology.

[18]  I. Thompson,et al.  Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial , 2018, The Lancet.

[19]  S. Daneshmand,et al.  Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity. , 2017, European urology.

[20]  P. Christos,et al.  Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. , 2015, European urology.

[21]  P. Warde,et al.  Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. , 2015, The Journal of urology.

[22]  B. Carver,et al.  Impact of age on clinicopathological outcomes and recurrence‐free survival after the surgical management of nonseminomatous germ cell tumour , 2012, BJU international.

[23]  M. Remzi,et al.  Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. , 2012, European urology.

[24]  M. Schrader,et al.  Prognostic clinical parameters to predict the necessity of reconstructive vascular surgery for patients who undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for advanced nonseminatous germ cell tumors (NSGCT). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Miceli,et al.  Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. , 2010, European urology.

[26]  V. Reuter,et al.  Evaluation of lymph node counts in primary retroperitoneal lymph node dissection , 2010, Cancer.

[27]  R. Motzer,et al.  Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Einhorn,et al.  Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.

[29]  F. Algaba,et al.  EAU Guidelines on Testicular Cancer , 2001, European Urology.